Clinical Trials & Datasets
Our research builds on rich, high-quality data collected from retrospective databases and prospective clinical trials of breast cancer. Over the years, we have generated and curated a range of datasets that reflect our multidisciplinary focus — integrating clinical, molecular, imaging, and computational perspectives to better understand breast cancer, treatment pathways and improve patient outcomes.
These datasets span:
- Clinical cohorts with comprehensive treatment and outcome information
- Molecular profiling data, including genomics, transcriptomics, and proteomics
- Digital pathology images and annotations
- Longitudinal and real-world data linking molecular features with clinical courses
- AI-ready multimodal datasets for integrative model development and validation
We value collaboration and believe data sharing accelerates discovery. While some datasets are already available through public repositories, others can be shared upon request in accordance with ethical and legal requirements governing patient data.
If you are interested in accessing or collaborating around any of our datasets, please contact us — we are always open to partnerships that advance cancer research and improve patient care.
A randomized neoadjuvant trial in HER2-positive early breast cancer comparing trastuzumab deruxtecan with standard preoperative anti-HER2 therapy and enabling biology-driven treatment selection.
Modalities:
A retrospective cohort comprising around 100 patients with TNBC who have underwent standard of care chemo-immunotherapy treatment (KN522 regimen), will be expanded with international collaborations soon.
Modalities:
A randomized phase II neoadjuvant study in HER2-positive breast cancer evaluating efficacy, safety, and response-predictive biomarkers across anti-HER2 treatment regimens.
Modalities:
A randomized phase II neoadjuvant trial in luminal B / HR+ breast cancer testing response-guided strategies that compare standard chemotherapy with CDK4/6-inhibitor–based endocrine approaches and integrated multi-omics biomarker analyses.
Modalities:
A phase III trial in high-risk early breast cancer comparing tailored dose-dense adjuvant chemotherapy versus standard scheduling to improve recurrence outcomes while evaluating treatment tolerance.
Modalities:
A translational neoadjuvant study aiming to identify molecular and functional imaging markers that predict early treatment response in breast cancer.
Modalities: longitudinal WES, snRNA, mfIHC, Proteomics
A randomized, multicenter phase II trial which compared three different regimens as adjuvant treatment for completely resected breast cancer.
Modalities:
A randomized first-line metastatic breast cancer trial comparing epirubicin + paclitaxel with or without capecitabine (TEX) and linking outcomes to tumor biology.
Modalities:
A randomized phase II study in HR+/HER2− advanced breast cancer with endocrine resistance comparing palbociclib + fulvestrant versus capecitabine to define optimal treatment and resistance biology.
Modalities:
A biomarker-focused study in HER2-negative metastatic breast cancer treated with bevacizumab + paclitaxel, designed to discover predictors of response and mechanisms of resistance using longitudinal sampling.
Modalities:
